Studies show that 40.8% of patients with hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer had AKT pathway alterations, and the most observed adverse events with capivasertib treatment were rash (in 12.1% of patients) and diarrhea (in 9.3% of patients), and phase I/II studies showed efficacy of capivasertib as a single agent or as a combination therapy with paclitaxel and fulvestrant in hormone receptor (HR)-positive, HER2-negative breast cancer [22]. Here, ERBB2 is linked to breast carcinoma.